Universal-Beteiligungs- und Servicegesellschaft’s Heron Therapeutics HRTX Stock Holding History

Universal-Beteiligungs- und Servicegesellschaft’s Portfolio HRTX Stock Details HRTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$367K	Buy	+458,766	New	+$532K	﹤0.01%	1811

Other funds holding HRTX

RCMNY

Rubric Capital Management (New York) New York $9.44B AUM 68.42% 1-Year Est. Return

Clearline Capital New York $1.93B AUM 38.13% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return

VCIM

Velan Capital Investment Management Alpharetta, Georgia $160M AUM 517.12% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Tejara Capital London, United Kingdom $303M AUM 5.43% 1-Year Est. Return

TCM

Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return

PCM

Palisade Capital Management Fort Lee, New Jersey $3B AUM 14% 1-Year Est. Return

Universal-Beteiligungs- und Servicegesellschaft's HRTX Position: Q1 2026 in Review

Universal-Beteiligungs- und Servicegesellschaft opened a new position in Heron Therapeutics (HRTX) in Q1 2026: 458,766 shares worth $367K. The stake represents ﹤0.01% of the portfolio and ranks #1811 among its holdings.

167 funds tracked by Wall St. Rank hold HRTX as of Q1 2026.

Universal-Beteiligungs- und Servicegesellschaft held 458,766 shares of Heron Therapeutics worth $367K as of Q1 2026.
Heron Therapeutics was a new Universal-Beteiligungs- und Servicegesellschaft position in Q1 2026.
Heron Therapeutics made up ﹤0.01% of Universal-Beteiligungs- und Servicegesellschaft's portfolio in Q1 2026, its #1811 holding.
167 funds tracked by Wall St. Rank held Heron Therapeutics as of Q1 2026.

Based on Universal-Beteiligungs- und Servicegesellschaft's 13F filing for Q1 2026, filed 11 May 2026.